Compare DexCom, Inc. (DXCM) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs 3M Company — how do they compare? DexCom, Inc. trades at $89.4 (market cap $33.79B), while 3M Company trades at $183.92 (market cap $94.44B). The key difference: 3M Company is far larger — about 2.8× DexCom, Inc.'s market cap, and 3M Company pays a 1.7% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MMM | |
|---|---|---|
Market Cap | $33.79B | $94.44B |
Sector | Health | Industrials |
52-Week High | $89.53 | $183.13 |
52-Week Low | $54.84 | $141.10 |
Enterprise Value | $33.24B | $103.67B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.
The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
